Burden of long-term OCS use in Patients with Severe Asthma. Professor Liam heaney

Burden of long-term OCS use in Patients with Severe Asthma.

Professor Liam Heaney (Professor of Respiratory Medicine) discusses the prevalence rates of morbidities associated with systemic corticosteroid therapy in severe asthma patients, the lifetime costs associated with long-term exposure as well as healthcare costs to the NHS.

Disclosures

Academic Lead for the UK MRC Consortium for Stratified Medicine in Severe Asthma – Industrial Pharma partners Amgen, AstraZeneca, Medimmune, Janssen, Novartis, Roche / Genentech, GlaxoSmithKline, and Boehringer Ingelheim. Project grant funding from Medimmune, Novartis UK, Roche / Genentech, and GlaxoSmithKline. Advisory Boards / Lectures supported by Novartis, Roche / Genentech, GlaxoSmithKline, Teva, and Vectura. Travel funding to international respiratory meetings (AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, Teva, and GlaxoSmithKline). Taken part in asthma clinical trials (GlaxoSmithKline, Schering Plough, Synairgen, Novartis, and Roche / Genentech) for which his institution was remunerated